Such depression was mitigated by fluvoxamine treatment producing considerable augmentation in nNOS, PSD-95, and NMDAR levels by 1.45-, 2.86- and 4.53-folds, respectively, as related to the KET group. Here, NOS1 is linked to depressive symptom measurement.